Is increasing urinary albumin a better marker for microvascular than for macrovascular complication of type 2 diabetes mellitus?
LncRNA LYPLAL1-DT screening from type 2 diabetes with macrovascular complication contributes protective effects on human umbilical vein endothelial cells via regulating the miR-204-5p/SIRT1 axis.
Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.
Wu Y, Ding Y, Tanaka Y, Zhang W.
Int J Med Sci. 2014 Sep 6;11(11):1185-200. doi: 10.7150/ijms.10001. eCollection 2014.
Type 2 diabetes.
Chatterjee S, Khunti K, Davies MJ.
Lancet. 2017 Jun 3;389(10085):2239-2251. doi: 10.1016/S0140-6736(17)30058-2. Epub 2017 Feb 10.
Risk factors for type 2 diabetes mellitus.
Fletcher B, Gulanick M, Lamendola C.
J Cardiovasc Nurs. 2002 Jan;16(2):17-23. doi: 10.1097/00005082-200201000-00003.
Macrovascular Complications of Type 2 Diabetes Mellitus.
Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T.
Curr Vasc Pharmacol. 2020;18(2):110-116. doi: 10.2174/1570161117666190405165151.
Sex differences in type 2 diabetes.
Kautzky-Willer A, Leutner M, Harreiter J.
Diabetologia. 2023 Jun;66(6):986-1002. doi: 10.1007/s00125-023-05891-x. Epub 2023 Mar 10.
Type-2 diabetes mellitus and cardiovascular disease.
Henning RJ.
Future Cardiol. 2018 Nov;14(6):491-509. doi: 10.2217/fca-2018-0045. Epub 2018 Nov 9.
[Exercise and oxidative stress in type 2 diabetes mellitus].
Poblete-Aro C, Russell-Guzmán J, Parra P, Soto-Muñoz M, Villegas-González B, Cofré-Bolados C, Herrera-Valenzuela T.
Rev Med Chil. 2018 Mar;146(3):362-372. doi: 10.4067/s0034-98872018000300362.
A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors.
Izzo A, Massimino E, Riccardi G, Della Pepa G.
Nutrients. 2021 Jan 9;13(1):183. doi: 10.3390/nu13010183.
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B.
Lancet. 2007 Sep 8;370(9590):829-40. doi: 10.1016/S0140-6736(07)61303-8.
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms.
Massimino E, Izzo A, Riccardi G, Della Pepa G.
Cells. 2021 Aug 1;10(8):1958. doi: 10.3390/cells10081958.
